MSD is currently managing temporary supply shortages of the preservative-free (PF) formulation of Cosopt® (dorzolamide hydrochloride-timolol maleate).
The shortage of Cosopt PF is as a result of increased global demand and a number of manufacturing issues experienced in 2012 that have reduced production capacity at manufacturing sites.
In order to meet the needs of the majority of patients who need preservative free formulations of MSD's ophthalmics products, MSD will be prioritising current production capacity to manufacture Cosopt PF at this time.
In addition, as a result of the growing global demand, MSD will be increasing its production capacity in the US.
Where patients have difficulty in obtaining this medication, they are advised to consult their healthcare professional to discuss the appropriate course of action for them.